Krystal Biotech shares jump as Q2 results exceed expectations

Published 04/08/2025, 13:24
Krystal Biotech shares jump as Q2 results exceed expectations

Investing.com -- Krystal Biotech , Inc. (NASDAQ:KRYS) reported second-quarter earnings and revenue that surpassed analyst expectations, driven by strong sales of its VYJUVEK treatment for dystrophic epidermolysis bullosa (DEB). The biotech company posted adjusted earnings per share of $1.29, beating the analyst estimate of $1.22, while revenue reached $96.04 million, exceeding the consensus forecast of $92.24 million.

The company’s quarterly revenue represented a 36.6% increase compared to the $70.3 million reported in the same quarter last year. Following the announcement, Krystal Biotech shares jumped 3.8% as investors responded positively to the earnings and revenue beat.

"With the approval of VYJUVEK in Europe and Japan, we are on the cusp of a global expansion that will build on our U.S. sales momentum and dramatically expand VYJUVEK access to DEB patients around the world," said Krish S. Krishnan, Chairman and CEO of Krystal Biotech.

The company reported that it has secured over 575 reimbursement approvals for VYJUVEK in the U.S. and maintains strong nationwide access. Patient compliance with weekly treatment while on the drug was 82% as of the end of the quarter. Gross margin for the quarter was 93%.

Krystal Biotech is preparing to launch VYJUVEK in Japan before the end of 2025 following approval by Japan’s Ministry of Health, Labour and Welfare in July. The company is also working to enable its first European launches in Germany in the third quarter and France in the fourth quarter.

The company ended the quarter with a strong financial position, reporting $820.8 million in cash, cash equivalents, and investments as of June 30, 2025. Net income for the quarter was $38.3 million, compared to $15.6 million in the same period last year.

Krystal Biotech maintained its full-year 2025 guidance for non-GAAP research and development and selling, general and administrative expenses of $150 million to $175 million.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.